

# Value of Central Venous to Arterial CO<sub>2</sub> Difference after Early Goal-directed Therapy in Septic Shock Patients

David Theophilo Araujo<sup>1</sup>, Vinicius Brenner Felice<sup>2</sup>, Andre Felipe Meregalli<sup>3</sup>, Gilberto Friedman<sup>4</sup>

## ABSTRACT

**Background and aims:** Venous to arterial difference of carbon dioxide (Pv-aCO<sub>2</sub>) tracks tissue blood flow. We aimed to evaluate if Pv-aCO<sub>2</sub> measured from a superior central vein sample is a prognostic index (ICU length of stay, SOFA score, 28th mortality rate) just after early goal-directed therapy (EGDT) comparing its ICU admission values between patients with normal and abnormal (>6 mm Hg) Pv-aCO<sub>2</sub>. As secondary objectives, we evaluated the relationship of Pv-aCO<sub>2</sub> with other variables of perfusion during the 24 hours that followed EGDT.

**Materials and methods:** Prospective observational study conducted in an academic ICU adult septic shock patients after a 6-hour complete EGDT. Hemodynamic measurements, arterial/central venous blood gases, and arterial lactate were obtained on ICU admission and after 6, 18 and 24 hours.

**Results:** Sixty patients were included. Admission Pv-aCO<sub>2</sub> values showed no prognostic value. Admission Pv-aCO<sub>2</sub> (ROC curve 0.527 [CI 95% 0.394 to 0.658]) values showed low specificity and sensitivity as predictors of mortality. There was a difference observed in the mean Pv-aCO<sub>2</sub> between nonsurvivors (NS) and survivors (S) after 6 hours. Central venous oxygen saturation (ScvO<sub>2</sub>) and Pv-aCO<sub>2</sub> showed significant correlation (R2 = -0.41, P < 0.0001). Patients with normal ScvO<sub>2</sub> (>70%) and abnormal Pv-aCO<sub>2</sub> (>6 mm Hg) showed higher SOFA scores. Normal Pv-aCO<sub>2</sub> group cleared their lactate levels in comparison to the abnormal Pv-aCO<sub>2</sub> group.

**Conclusion:** In septic shock, admission Pv-aCO<sub>2</sub> after EGDT is not related to worse outcomes. An abnormal Pv-aCO<sub>2</sub> along with a normal ScvO<sub>2</sub> is related to organ dysfunction.

**Keywords:** Central venous saturation, Lactate, Mortality, Septic shock, Venous to arterial difference of CO<sub>2</sub>.

*Indian Journal of Critical Care Medicine* (2019): 10.5005/jp-journals-10071-23262

## INTRODUCTION

Septic shock is a condition in which tissue perfusion is inadequate, leading to multi-organ dysfunction and death.<sup>1</sup> An early optimization of systemic hemodynamic parameters seems to improve outcomes in shock states, reinforcing the idea that is fundamental to reestablish blood flow early in shock.<sup>2</sup> However, maintaining normal systemic hemodynamic parameters does not always guarantee adequate tissue perfusion.<sup>3,4</sup>

As a major determinant of oxygen supply, adequacy of blood flow is a fundamental variable to be evaluated.<sup>5</sup> The venous to arterial difference of partial pressure of carbon dioxide (Pv-aCO<sub>2</sub>) is an index that has shown to be inversely correlated with the cardiac output (CO) in several shock states.<sup>6-9</sup> Studies using both mixed venous or central venous PCO<sub>2</sub> showed similar inverse curvilinear correlation with CO.<sup>10,11</sup> The enlargement venous to arterial CO<sub>2</sub> difference in animal models is shown during ischemic hypoxia.<sup>12-14</sup> Thus, venous accumulation of CO<sub>2</sub> is secondary either to a reduced blood flow and/or to anaerobic metabolism.<sup>15</sup> Although a few studies demonstrated that the correlation between blood flow and Pv-aCO<sub>2</sub> sounds physiological and it was associated with poor outcomes,<sup>16,17</sup> others questioned a clear prognostic implication.<sup>6,18,19</sup>

Several studies showed that oxygen parameters are normalized at ICU admission, showing that early global resuscitation might be partial or completely achieved.<sup>20-23</sup> Recent studies have challenged early goal directed therapy (EGDT) as a strategy to be followed, but all these studies initiated EGDT after significant volume repletion and ScvO<sub>2</sub> was close to normal at randomization, suggesting that blood flow was already restored.<sup>21-23</sup> Thus, studies have demonstrated that mixed or venous oxygen saturation normal values may not depict regional or tissues perfusion abnormalities.<sup>4,24</sup> Interestingly, Vallet et al. reported that in adult septic patients with septic shock, having

<sup>1-4</sup>Central ICU, Santa Casa Hospital, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-graduação em Ciências Pneumológicas, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

**Corresponding Author:** Gilberto Friedman, Central ICU, Santa Casa Hospital, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-graduação em Ciências Pneumológicas, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, Phone: 55.51.33116649, e-mail: gfriedman@hcpa.edu.br

**How to cite this article:** Araujo DT, Felice VB, Meregalli AF, Friedman G. Value of Central Venous to Arterial CO<sub>2</sub> Difference after Early Goal-directed Therapy in Septic Shock Patients. *Indian J Crit Care Med* 2019;23(10):449-453.

**Source of support:** Nil

**Conflict of interest:** None

Pv-aCO<sub>2</sub> >6 mm Hg after achieving the goal ScvO<sub>2</sub> of 70% helped identify patients with ongoing hypoperfusion.<sup>24</sup>

Given that Pv-aCO<sub>2</sub> can track blood flow in the tissues, we asked if this index could identify hypoperfusion in septic shock patients admitted to the ICU after adequate EGDT. This investigation may add information to the use of this index to decide if additional increase in blood flow may help septic patients during EGDT. Thus, we aimed to evaluate if Pv-aCO<sub>2</sub> measured from a superior central vein sample is related with organ dysfunction and mortality in patients with septic shock after early resuscitation, comparing its ICU admission values between patients with normal and enlarged (>6 mm Hg) Pv-aCO<sub>2</sub>. As secondary objectives, we evaluated the relationship of Pv-aCO<sub>2</sub> with other variables of perfusion (lactate and central venous oxygen saturation) during the 24 hours that followed EGDT.

## MATERIALS AND METHODS

This prospective observational non-interventional clinical study was conducted in an 18-bedded general ICU of a university hospital. The study population consisted of adult ( $\geq 18$  years) septic patients admitted to the intensive care unit after EGDT that persisted with shock (need for vasopressors). Our EGDT included a bundle of interventions during 6 hours period that sought to obtain a mean arterial pressure (MAP)  $\geq 65$  mm Hg (a fluid challenge of at least 20 mL/kg and need of vasopressors), urine output  $>0.5$  mL/kg/h and a hemoglobin  $\geq 7$  g/dL. All patients were required to stay in the unit for at least 24 hours. Patients with liver cirrhosis, pregnancy, absence of a central line for any reason, incomplete EGDT, or considered without therapeutic perspective were excluded.

Measurements on admission had to be obtained in a window not greater than 2 hours after EGDT completion. All patients had to have a superior central venous line and an arterial catheter in place. Hemodynamic measurements and collection of arterial and venous blood gases, and lactate were performed on admission to the ICU and after 6 (T6), 12 (T12), 18 (T18) and 24 (T24) hours. Additional resuscitation (use of crystalloid or colloid and vasopressor) was held at the discretion of the attending physician, according to clinical judgment. Blood gas values were determined using a commercial blood-gas analyzer (Ciba-Corning, San Diego, CA, USA). Blood lactate concentrations were measured by an enzymatic technique (Cobas Mira Plus, Roche, Indianapolis, IN, USA).

This study was approved by the hospital ethics committee. Informed consent was waived because there was no intervention and the collection of blood samples was part of routine assistance protocols.

## OUTCOMES

The primary outcome assessed was 28th mortality. Other outcomes included ICU length of stay and organ dysfunction (sequential organ failure assessment score).

## STATISTICAL ANALYSIS

Statistical analyses were performed using SPSS v.18.0. Quantitative variables were expressed as mean  $\pm$  standard deviation. Qualitative variables were described as frequencies and percentages. The evolution of each variable during 24 hours was analyzed using a repeated-measures analysis of variance. The comparison of means was performed using the Student's *t* test for normally distributed variables and the Mann-Whitney test for variables with non-normal distribution (Kolmogorov-Smirnov test). The frequencies were analyzed using the Chi-squared test (or Fisher's test when appropriate). To evaluate the performance of Pv-aCO<sub>2</sub> on admission to predict death at 28th day, receiver operating characteristics (ROC) curve analysis was performed. The Spearman's rho was used to explore the relationship between Pv-aCO<sub>2</sub> and ScvO<sub>2</sub> on T0. Data are reported as means  $\pm$  standard deviations unless indicated otherwise. For statistical analysis, SPSS version 18.0 for windows (SPSS, Chicago, IL, USA) was used. The *p* value considered significant was  $<0.05$ .

## RESULTS

During a 12-month period, 112 patients were screened. After exclusions, a total of 60 patients were analyzed and 271 measures of Pv-aCO<sub>2</sub> were obtained, 57% within the normal range ( $<6$  mm

**Table 1:** Demographic, hemodynamic and oxygenation parameters at ICU admission for survivors and nonsurvivors after 28 days

	Survivors (n = 32)	Nonsurvivors (n = 28)
AGE (years)	54 $\pm$ 15	61 $\pm$ 12
APACHE II	24 $\pm$ 8	27 $\pm$ 6
SOFA Day 1	9.7 $\pm$ 3.5	9.9 $\pm$ 2.9
SOFA Day 2	7.5 $\pm$ 3.7	9.0 $\pm$ 3.7
SOFA Day 3 (s = 31, ns = 27)	5.5 $\pm$ 4.4	8.3 $\pm$ 4.1*
Mechanical ventilation	27	26
ICU length of stay (days)	15 [9-38]	14[9-20]
Pv-aCO <sub>2</sub> (mm Hg)	6.1 $\pm$ 4.1	5.6 $\pm$ 3.5
MAP (mm Hg)	74 $\pm$ 17	67 $\pm$ 14
HR (beats/min)	105 $\pm$ 19	106 $\pm$ 17
CVP (mm Hg)	16 $\pm$ 7	14 $\pm$ 6
Diuresis (mL/kg/h)	0.4 $\pm$ 0.6	0.5 $\pm$ 0.9
SaO <sub>2</sub> (%)	96 $\pm$ 5	95 $\pm$ 8
ScvO <sub>2</sub> (%)	72 $\pm$ 10	75 $\pm$ 9
Arterial lactate (mmol/L)	2.6 $\pm$ 2.2	3.3 $\pm$ 2.8
Norepinephrine ( $\mu$ g/kg/min)	0.16 [0.08–0.27]	0.16 [0.07–0.26]

APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment score; Pv-aCO<sub>2</sub>, venous to arterial difference of partial pressure of carbon dioxide; MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure; SaO<sub>2</sub>, arterial hemoglobin oxygen saturation; ScvO<sub>2</sub>, central venous hemoglobin oxygen saturation. \**p*  $< 0.05$ .

Hg). Admission ScvO<sub>2</sub> values were normal for 41 patients (68%). The mortality rate at 28 days was 43% (26/60). Survivors showed a significant reduction in SOFA score during 3 days follow-up (Table 1).

The admission Pv-aCO<sub>2</sub> showed no difference with regard to any possible outcome when categorized in normal and abnormal (Table 2). Admission Pv-aCO<sub>2</sub> (ROC curve 0.527 [CI 95% 0.394 to 0.658]), ScvO<sub>2</sub> (0.586 [CI 95% 0.452 to 0.712]) and arterial lactate (0.589 [CI 95% 0.455 to 0.715]) values showed low specificity and sensitivity to predict mortality. Normal or abnormal Pv-aCO<sub>2</sub> values in each time did not show statistical difference for 28th mortality, ICU mortality and SOFA scores.

There was a difference observed in mean Pv-aCO<sub>2</sub> between NS and S in T6 (Fig. 1). ScvO<sub>2</sub> was similar for both S and NS. Survivors had lower lactate levels at all times and at T12, the difference reached statistical significance (Fig. 1). At admission, patients with normal Pv-aCO<sub>2</sub> values did not show any outcome differences when compared to those with normal and low ScvO<sub>2</sub> (data not shown). However, patients with normal ScvO<sub>2</sub> values but with enlarged Pv-aCO<sub>2</sub> showed higher SOFA score values during follow-up (Table 3).

Central venous oxygen saturation and Pv-aCO<sub>2</sub> showed a significant but weak correlation ( $R^2 = -0.41$ ,  $P < 0.0001$ ). Central venous oxygen saturation was significantly higher in the first 6 hours in patients with normal Pv-aCO<sub>2</sub> (Fig. 2). Patients in the normal Pv-aCO<sub>2</sub> group cleared their lactate levels in comparison to the abnormal Pv-aCO<sub>2</sub> group (Fig. 2).

## DISCUSSION

In our study, Pv-aCO<sub>2</sub> after EGDT completion did not correlate with mortality in the ICU or after 28 days, with a longer ICU stay or greater organ dysfunction. Different from others, we did not find

**Table 2:** Demographic, hemodynamic and oxygenation parameters of patients with normal ( $\leq 6$  mm Hg) and abnormal ( $>6$  mm Hg) Pv-aCO<sub>2</sub> at ICU admission

	Normal (n = 36)	Abnormal (n = 24)
Age (years)	56±13	60±15
APACHE II	26±8	24±7
SOFA day 1	9.6±2.9	10.0±3.7
SOFA day 2	7.9±3.5	8.9±4.1
SOFA day 3	7.3±4.7	6.6±4.4
Mechanical ventilation	32	21
28th day mortality rate (%)	47	46
ICU length of stay (days)	20±14	20±22
Pv-aCO <sub>2</sub> (mm Hg)	3.27±1.71	9.80±2.48*
MAP (mm Hg)	72±17	70±16
HR (beats/min)	107±19	103±17
CVP (mm Hg)	14±6	16±9
Diuresis (mL/kg/h)	0.51±0.77	0.43±0.65
SaO <sub>2</sub> (%)	97±8	96±7
ScvO <sub>2</sub> (%)	77±9	68±8*
Arterial lactate (mmol/L)	2.25 [1.17-3.55]	2.3 [1.25-3.90]
Norepinephrine (µg/Kg/min)	0.16 [0.08-0.24]	0.18 [0.08-0.28]


APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment score; MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure; SaO<sub>2</sub>, arterial hemoglobin oxygen saturation; ScvO<sub>2</sub>, central venous hemoglobin oxygen saturation. \* $p < 0.001$ .

that an abnormal Pv-aCO<sub>2</sub> after apparent global hemodynamic resuscitation identified patients at risk to developed organ dysfunction or to die. The differences between admission normal and abnormal Pv-aCO<sub>2</sub> groups relied on physiological parameters with logical results. Abnormal Pv-aCO<sub>2</sub> was associated with a lower ScvO<sub>2</sub> and higher lactate values.

In addition, concerning ICU or 28th Day mortality rates and the degree of organ dysfunction in any of the three assessments by the SOFA score we did not find differences between Pv-aCO<sub>2</sub> groups. Our study evaluated patients after EGDT, which may have led to the inclusion of a high number of patients with high to normal blood flow. It is well known that patients with sepsis, a scenario that is usually associated with a high cardiac output (hyperdynamic state), is a condition in which the Pv-aCO<sub>2</sub> has the worst correlation with cardiac output.<sup>25</sup>

A look at the perfusion parameters also showed small differences between groups and for most patients lactate values were not elevated. Thus, we speculated that global tissue perfusion was restored for majority of the patients. Of 271 measurements obtained in this study, 57 were normal and many values on the abnormal Pv-aCO<sub>2</sub> group were below 8 mm Hg, so that it could be inferred that the majority of patients had enough blood flow just after EGDT completion. KM Ho and colleagues showed that the usefulness of the Pv-aCO<sub>2</sub> appears to be limited to its negative predictive value, to exclude a low cardiac output when it is within its normal range.<sup>26</sup> Here one should also be cautious in interpreting the outcomes findings as the study was underpowered to show the prognostic value of Pv-aCO<sub>2</sub> (small sample size), but that was evidenced in other studies.<sup>16,17</sup>

No differences in lactate levels were found between the two groups of Pv-aCO<sub>2</sub> at the time of admission. Similar findings were



**Figs 1A to C:** Venous to arterial CO<sub>2</sub> difference (Pv-aCO<sub>2</sub>), central venous saturation (ScvO<sub>2</sub>) and blood lactate values in survivors (S) and non-survivors (NS) during 24 hours. \* $p < 0.05$  S vs NS after 12 hours

observed in other studies with septic shock.<sup>6,27,28</sup> This can be explained by the fact that the Pv-aCO<sub>2</sub> is not a marker of tissue hypoxia (such as lactate), but of the adequacy of blood flow to remove tissue CO<sub>2</sub>.<sup>12,14,15</sup> However, although with marginal significance ( $p = 0.065$ ), patients with a normal Pv-aCO<sub>2</sub> cleared their blood lactate over 24 hours as shown by others.<sup>16,27</sup> Interestingly,

**Table 3:** Comparisons of clinical data at admission between patients that normalized ScvO<sub>2</sub> values with a normal and abnormal Pv-aCO<sub>2</sub> values


	ScvO <sub>2</sub> > 70% and Pv-aCO <sub>2</sub> ≤ 6 mm Hg (n = 31)	ScvO <sub>2</sub> > 70% and Pv-aCO <sub>2</sub> > 6 mm Hg (n = 10)
SOFA day 1	9.5±2.8	12±3.9*
SOFA day 2	7.7±3.4	9.8±4.6
SOFA day 3	6.1±4.4	8.4±4.8
Pv-aCO <sub>2</sub> (mm Hg)	3.4±1.8	9.9±2.9 <sup>#</sup>
MAP (mm Hg)	71±16	70±17
HR (beats/min)	106±20	101±20
CVP (mm Hg)	13±5	16±12
Diuresis (mL/kg/h)	0.6±0.8	0.5±0.8
ScvO <sub>2</sub> (%)	80±6	75±5*
Arterial lactate (mmol/L)	2.2 [1.1–3.2]	3.1 [1.3–4.9]
Norepinephrine (µg/Kg/min)	0.2 [0.1–0.2]	0.2 [0.1–0.3]
28 day mortality n (%)	15(48)	5 (50)

APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment score; Pv-aCO<sub>2</sub>, venous to arterial difference of partial pressure of carbon dioxide; MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure; ScvO<sub>2</sub>, central venous hemoglobin oxygen saturation. \**p* < 0.05, <sup>#</sup>*p* < 0.001.

the lactate clearance was accompanied by a lower ScvO<sub>2</sub> during the first 6 hours which together may indicate a higher blood flow and less hypoperfusion in several patients. Moreover, hyperlactatemia in septic conditions is complex since lactate accumulation may happen during accelerated aerobic generation and/or slow clearance.<sup>29</sup>

The widening of the arterial venous CO<sub>2</sub> difference was associated with reduced venous saturation, but this correlation, however significant, was poor. The weakness of this association in previously resuscitated patients, such as in this condition, may suggest that even after normalization of venous saturation there is still room to increase the blood flow. In our study, patients with ScvO<sub>2</sub> 70% but with an abnormal Pv-aCO<sub>2</sub> had more organ dysfunctions since admission. Venous saturation may be falsely normal when oxygen capabilities are compromised and an enlarged Pv-aCO<sub>2</sub> may identify a lack of tissue blood flow.<sup>24</sup> In addition, Mahajan et al. showed that a normal Pv-aCO<sub>2</sub> together with a normal ScvO<sub>2</sub> was even more associated with mortality.<sup>28</sup> A normal Pv-aCO<sub>2</sub> in the presence of tissue hypoperfusion or ongoing organ dysfunction may reflect cytopathic dysoxia or microcirculatory abnormalities.<sup>15,30,31</sup> In our study, the weakness of its prognostic value, even in patients considered well resuscitated, may suggest that after global resuscitation the disease process continues. In conjunction with the complex relationship of these variables and cardiac output, this suggests that when oxygen extraction capacity is altered, guiding resuscitation by systemic parameters is a challenge in more advanced stages of septic shock.

Finally, although Pv-aCO<sub>2</sub> as an isolated parameter does not serve to guide resuscitation, recently the use of this variable in a resuscitation proposal that integrates several parameters with a physiological view seems to be useful.<sup>32</sup> The Andromeda study, besides suggesting that it is possible to guide resuscitation by capillary refill time, used Pv-aCO<sub>2</sub> as one of the targets to be pursued.



**Figs 2A and B:** Central venous O<sub>2</sub> saturation (ScvO<sub>2</sub>) and blood lactate values among normal (Pv-aCO<sub>2</sub> ≤ 6 mm Hg) and abnormal (Pv-aCO<sub>2</sub> >6 mm Hg) venous-arterial carbon dioxide groups patients during 24 hours. \**p* < 0.05 abnormal vs normal. <sup>#</sup>*p* = 0.025 over 24 hours in abnormal group

The study has limitations beyond the small sample size already highlighted. The venous blood sample is central and not mixed, and although there is reasonable agreement, the differences cannot be neglected. Second, the hemodynamic and perfusion changes that occurred during subsequent hours were not necessarily the result of targeted interventions, but may simply be changes related to the disease process. Third, although Pv-aCO<sub>2</sub> enlargement may suggest insufficient blood flow to remove tissue CO<sub>2</sub>, venoarterial gradients are the result of interactions between CO<sub>2</sub> production, CO<sub>2</sub> dissociation curve, hemoglobin, blood flow, microcirculatory and cell changes.

**CONCLUSION**

This study showed that the admission Pv-aCO<sub>2</sub> after EGDT is not associated with worse outcomes. The possible physiologic explanation is that blood flow was restored for most patients. In the future, studies with larger numbers of patients may demonstrate that Pv-aCO<sub>2</sub> could be a useful complementary perfusion clinical parameter and help identify patients who remain inadequately managed when the hemodynamic optimization has been reached.



## REFERENCES

- Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013;41(2):580–637.
- Hernandez G, Cavalcanti AB, Ospina-Tascon G, Zampieri FG, Dubin A, Hurtado FJ et al. Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK-a randomized controlled trial. *Ann Intensive Care* 2018;8(1):52.
- Meregalli A, Oliveira RP, Friedman G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. *Crit Care* 2004;8(2):R60–R65.
- Puskarich MA, Trzeciak S, Shapiro NI, Heffner AC, Kline JA, Jones AE. Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock. *Resuscitation* 2011;82(10):1289–1293.
- Friedman G, De Backer D, Shahla M, Vincent JL. Oxygen supply dependency can characterize septic shock. *Intensive Care Med* 1998;24(2):118–123.
- Bakker J, Vincent JL, Gris P, Leon M, Coffernils M, Kahn RJ. Veno-arterial carbon dioxide gradient in human septic shock. *Chest* 1992;101(2):509–515.
- Rackow EC, Astiz ME, Mecher CE, Weil MH. Increased venous-arterial carbon dioxide tension difference during severe sepsis in rats. *Crit Care Med* 1994;22(1):121–125.
- Zhang H, Vincent JL. Arteriovenous differences in PCO<sub>2</sub> and pH are good indicators of critical hypoperfusion. *Am Rev Respir Dis* 1993;148(4 Pt 1):867–871.
- Durkin R, Gergits MA, Reed JF, III, Fitzgibbons J. The relationship between the arteriovenous carbon dioxide gradient and cardiac index. *J Crit Care* 1993;8(4):217–221.
- Cuschieri J, Rivers E, Donnino M, Katilius M, Jacobsen G, Nguyen B et al. Central venous-arterial carbon dioxide difference as an indicator of cardiac index. *Intensive Care Med*. 2005;31(6):818–822.
- Tsaousi GG, Karakoulas KA, Amaniti EN, Soultati ID, Zouka MD, Vasilakos DG. Correlation of central venous-arterial and mixed venous-arterial carbon dioxide tension gradient with cardiac output during neurosurgical procedures in the sitting position. *Eur J Anaesthesiol* 2010;27(10):882–889.
- Vallet B, Teboul JL, Cain S, Curtis S. Venoarterial CO<sub>2</sub> difference during regional ischemic or hypoxic hypoxia. *J Appl Physiol* (1985) 2000;89(4):1317–1321.
- Neviere R, Chagnon JL, Teboul JL, Vallet B, Wattel F. Small intestine intramucosal PCO<sub>2</sub> and microvascular blood flow during hypoxic and ischemic hypoxia. *Crit Care Med* 2002;30(2):379–384.
- Dubin A, Murias G, Estenssoro E, Canales H, Badie J, Pozo M et al. Intramucosal-arterial PCO<sub>2</sub> gap fails to reflect intestinal dysoxia in hypoxic hypoxia. *Crit Care* 2002;6(6):514–520.
- Dubin A, Estenssoro E. Mechanisms of tissue hypercarbia in sepsis. *Front Biosci* 2008;13:1340–1351.
- Ospina-Tascon GA, Bautista-Rincon DF, Umana M, Tafur JD, Gutierrez A, Garcia AF et al. Persistently high venous-to-arterial carbon dioxide differences during early resuscitation are associated with poor outcomes in septic shock. *Crit Care* 2013;17(6):R294.
- Muller G, Mercier E, Vignon P, Henry-Lagarrigue M, Kamel T, Desachy A et al. Prognostic significance of central venous-to-arterial carbon dioxide difference during the first 24 hours of septic shock in patients with and without impaired cardiac function. *Br J Anaesth* 2017;119(2):239–248.
- Akamatsu T, Inata Y, Tachibana K, Hatachi T, Takeuchi M. Elevated Central Venous to Arterial CO<sub>2</sub> Difference Is Not Associated with Poor Clinical Outcomes After Cardiac Surgery With Cardiopulmonary Bypass in Children. *Pediatr Crit Care Med* 2017;18(9):859–862.
- Morel J, Grand N, Axiotis G, Bouchet JB, Faure M, Auboyer C et al. High veno-arterial carbon dioxide gradient is not predictive of worst outcome after an elective cardiac surgery: a retrospective cohort study. *J Clin Monit Comput* 2016;30(6):783–789.
- Boulain T, Garot D, Vignon P, Lascarrou JB, Desachy A, Botoc V et al. Prevalence of low central venous oxygen saturation in the first hours of intensive care unit admission and associated mortality in septic shock patients: a prospective multicentre study. *Crit Care* 2014;18(6):609.
- Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD et al. Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. *Health Technol Assess* 2015;19(97):i–150.
- Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ et al. Goal-directed resuscitation for patients with early septic shock. *N Engl J Med* 2014;371(16):1496–1506.
- Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F et al. A randomized trial of protocol-based care for early septic shock. *N Engl J Med* 2014;370(18):1683–1693.
- Vallee F, Vallet B, Mathe O, Parraguette J, Mari A, Silva S et al. Central venous-to-arterial carbon dioxide difference: an additional target for goal-directed therapy in septic shock? *Intensive Care Med* 2008;34(12):2218–2225.
- Mallat J, Lemyze M, Tronchon L, Vallet B, Thevenin D. Use of venous-to-arterial carbon dioxide tension difference to guide resuscitation therapy in septic shock. *World J Crit Care Med* 2016;5(1):47–56.
- Ho KM, Harding R, Chamberlain J. A comparison of central venous-arterial and mixed venous-arterial carbon dioxide tension gradient in circulatory failure. *Anaesth Intensive Care* 2007;35(5):695–701.
- Mallat J, Pepy F, Lemyze M, Gasan G, Vangrunderbeeck N, Tronchon L et al. Central venous-to-arterial carbon dioxide partial pressure difference in early resuscitation from septic shock: a prospective observational study. *Eur J Anaesthesiol* 2014;31(7):371–380.
- Mahajan RK, Peter JV, John G, Graham PL, Rao SV, Pinsky MR. Patterns of central venous oxygen saturation, lactate and veno-arterial CO<sub>2</sub> difference in patients with septic shock. *Indian J Crit Care Med* 2015;19(10):580–586.
- Vincent JL, Quinteiros E Silva, Couto L, Jr., Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. *Crit Care* 2016;20(1):257.
- Ospina-Tascon GA, Umana M, Bermudez WF, Bautista-Rincon DF, Valencia JD, Madrinan HJ et al. Can venous-to-arterial carbon dioxide differences reflect microcirculatory alterations in patients with septic shock? *Intensive Care Med* 2016;42(2):211–221.
- Fink MP. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. *Crit Care Clin* 2001;17(1):219–237.
- Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. *JAMA* 2019;321(7):654–664.